BioCentury
ARTICLE | Financial News

CDH leads Harbour BioMed round

January 23, 2018 12:08 AM UTC

Harbour BioMed (Shanghai, China) raised an undisclosed series A+ round led by new investor CDH Investments. Existing investor Advantech Capital participated.

This month, Harbour granted BeiGene Ltd. (NASDAQ:BGNE) and ImmunoChina Pharmaceuticals Co. Ltd. rights to its H2L2 transgenic mouse platform in a pair of antibody-related deals. Harbour's H2L2 mice generate human mAbs with both heavy and light chains (see BioCentury Extra, Jan. 8)...

BCIQ Company Profiles

HBM Holdings Ltd.